Nothing Special   »   [go: up one dir, main page]

DOP2006000210A - Compuestos de pirimidina amida como inhibidores de pgds - Google Patents

Compuestos de pirimidina amida como inhibidores de pgds

Info

Publication number
DOP2006000210A
DOP2006000210A DO2006000210A DO2006000210A DOP2006000210A DO P2006000210 A DOP2006000210 A DO P2006000210A DO 2006000210 A DO2006000210 A DO 2006000210A DO 2006000210 A DO2006000210 A DO 2006000210A DO P2006000210 A DOP2006000210 A DO P2006000210A
Authority
DO
Dominican Republic
Prior art keywords
amida
pyrimidine compounds
compound
pgds inhibitors
pgds
Prior art date
Application number
DO2006000210A
Other languages
English (en)
Inventor
Suzanne C Aldous
John Ziqi Jiang
Jinqi Lu
Liang Ma
Lan Mu
Harry Randall Munson
Jeffrey Stephen Sabol
Sukanthini Thurairatnam
Christopher Loren Vandeusen
Original Assignee
Aventis Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Inc filed Critical Aventis Pharma Inc
Publication of DOP2006000210A publication Critical patent/DOP2006000210A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Esta invención se refiere a un compuesto de fórmula (I): en la que R1, R2, R3 y L' son como se han definido anteriormente, una composición farmaceutica que comprende el compuesto, y el use del compuesto para tratar trastomos alergicos y/o inflamatorios, particularmente trastornos tales como rinitis alergica, asma y/o enfermedad pulmonar obstructiva crónica (COPD).
DO2006000210A 2005-10-04 2006-10-03 Compuestos de pirimidina amida como inhibidores de pgds DOP2006000210A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US72357005P 2005-10-04 2005-10-04

Publications (1)

Publication Number Publication Date
DOP2006000210A true DOP2006000210A (es) 2007-06-15

Family

ID=37635758

Family Applications (1)

Application Number Title Priority Date Filing Date
DO2006000210A DOP2006000210A (es) 2005-10-04 2006-10-03 Compuestos de pirimidina amida como inhibidores de pgds

Country Status (27)

Country Link
US (1) US8202863B2 (es)
EP (1) EP1937652B1 (es)
JP (1) JP5452925B2 (es)
KR (1) KR101457966B1 (es)
CN (2) CN101282943A (es)
AR (1) AR056871A1 (es)
AU (1) AU2006299428B2 (es)
BR (1) BRPI0616815A2 (es)
CA (1) CA2624749C (es)
CR (1) CR9832A (es)
DO (1) DOP2006000210A (es)
EC (1) ECSP088335A (es)
ES (1) ES2514471T3 (es)
IL (1) IL190411A (es)
MA (1) MA29925B1 (es)
MY (1) MY151172A (es)
NO (1) NO20082000L (es)
NZ (1) NZ567208A (es)
PE (2) PE20070589A1 (es)
RU (1) RU2420519C2 (es)
SG (1) SG166121A1 (es)
TN (1) TNSN08104A1 (es)
TW (1) TWI415839B (es)
UA (1) UA93213C2 (es)
UY (1) UY29840A1 (es)
WO (1) WO2007041634A1 (es)
ZA (1) ZA200802222B (es)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ566722A (en) * 2005-09-15 2010-11-26 Orchid Res Lab Ltd Novel pyrimidine carboxamides
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds
MX2008013194A (es) 2006-04-11 2008-12-01 Vertex Pharma Composiciones utiles como inhibidores de canales de sodio regulados por voltaje.
EP2129660A2 (en) 2006-12-19 2009-12-09 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
EP2132196A1 (en) 2007-02-26 2009-12-16 Pfizer Products Inc. Nicotinamide derivatives as inhibitors of h-pgds and their use for treating prostaglandin d2 mediated diseases
ES2663517T3 (es) * 2007-08-27 2018-04-13 Dart Neuroscience (Cayman) Ltd Compuestos terapéuticos de isoxazol
US8389734B2 (en) 2007-10-11 2013-03-05 Vertex Pharmaceuticals Incorporated Amides useful as inhibitors of voltage-gated sodium channels
NZ584519A (en) 2007-10-11 2012-07-27 Vertex Pharma Aryl amides useful as inhibitors of voltage-gated sodium channels
CA2701946A1 (en) * 2007-10-11 2009-04-16 Vertex Pharmaceuticals Incorporated Heteroaryl amides useful as inhibitors of voltage-gated sodium channels
CA2703220A1 (en) * 2007-11-13 2009-05-22 Pfizer Global Research And Development Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
AU2009211724B2 (en) * 2008-02-06 2013-05-16 Msd K.K. 3-substituted sulfonyl piperazine derivative
AU2009246446B2 (en) * 2008-05-13 2014-06-26 Cayman Chemical Company, Incorporated Methods for assaying compounds or agents for ability to displace potent ligands of hematopoietic prostaglandin D synthase
CA2725481A1 (en) 2008-06-18 2009-12-23 Pfizer Limited Nicotinamide derivatives
EP2307377A1 (en) 2008-06-18 2011-04-13 Pfizer Limited Nicotinamide derivatives
NZ592297A (en) 2008-09-22 2012-11-30 Cayman Chemical Co Inc 2-Aryl-5-heteroaryl pyridine and pyrimidine derivatives as pharmaceutical active agents
KR101367057B1 (ko) 2009-03-17 2014-02-25 (주)아모레퍼시픽 피부 자극 완화용 조성물
KR101252335B1 (ko) 2009-07-16 2013-04-08 (주)아모레퍼시픽 피부 노화 방지용 조성물
WO2010056044A2 (ko) * 2008-11-11 2010-05-20 (주)아모레퍼시픽 바닐로이드 수용체 길항제로 작용하는 신규 화합물, 이의 이성질체 또는 이의 약제학적으로 허용 가능한 염 및 이를 포함하는 약학 조성물
CN102341385B (zh) 2009-03-09 2014-01-15 大鹏药品工业株式会社 能够抑制前列腺素d合酶的哌嗪化合物
AU2010303439B2 (en) * 2009-10-08 2015-10-29 Sanofi Phenyloxadiazole derivatives as PGDS inhibitors
AU2011208139B2 (en) 2010-01-22 2014-10-23 Taiho Pharmaceutical Co., Ltd. Piperazine compound having a PGDS inhibitory effect
US9320723B2 (en) * 2010-05-03 2016-04-26 University Of Rochester Methods of treating thyroid eye disease
AU2011261164A1 (en) 2010-06-01 2012-12-13 The University Of Queensland Haematopoietic-prostaglandin D2 synthase inhibitors
CA2810489A1 (en) 2010-09-07 2012-03-15 Yoshihiro Urade Prostaglandin d synthase inhibitory piperidine compounds
KR101271223B1 (ko) 2011-01-27 2013-06-07 한국과학기술연구원 아미노피리미딘 유도체 및 이를 포함하는 세포외 신호조절 키나제의 제해제
AU2013207510A1 (en) 2012-01-06 2014-07-31 The Regents Of The University Of California Compositions, methods of use, and methods of treatment
WO2014029193A1 (en) * 2012-08-24 2014-02-27 Sunshine Lake Pharma Co., Ltd. Dihydropyrimidine compounds and their application in pharmaceuticals
US20210238162A1 (en) 2015-12-17 2021-08-05 Glaxosmithkline Intellectual Property Development Limited Chemical compounds
EP3429588B1 (en) * 2016-03-14 2024-09-18 Emory University Amide-sulfamide derivatives, compositions, and uses related to cxcr4 inhibition
JOP20190072A1 (ar) * 2016-10-13 2019-04-07 Glaxosmithkline Ip Dev Ltd مشتقات 1، 3 سيكلوبوتان ثنائي الاستبدال أو آزيتيدين كمثبطات للإنزيم المخلق للبروستاجلاندين d المكون للدم
JP2020523367A (ja) 2017-06-13 2020-08-06 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ Ｈ−ｐｇｄｓ阻害剤としての化学化合物
CN111655256B (zh) * 2017-10-29 2023-12-29 洪明奇 包含adam9抑制剂化合物的组合物
WO2019116256A1 (en) 2017-12-13 2019-06-20 Glaxosmithkline Intellectual Property Development Limited Fused pyridines which act as inhibitors of h-pgds
MX2020009887A (es) * 2018-03-23 2020-10-12 Step Pharma S A S Derivados de aminopiridina como inhibidores de ctps1.
EP3877384A1 (en) 2018-11-08 2021-09-15 GlaxoSmithKline Intellectual Property Development Ltd Chemical compounds
CA3182912A1 (en) * 2020-05-13 2021-11-18 Chdi Foundation, Inc. Htt modulators for treating huntington's disease
JPWO2021256569A1 (es) 2020-06-19 2021-12-23
EP4232425A4 (en) * 2020-10-23 2024-07-24 Nimbus Clotho Inc CTPS1 INHIBITORS AND USES THEREOF
CN113004208A (zh) * 2021-03-08 2021-06-22 沈阳药科大学 一种抑制黄嘌呤氧化酶活性的化合物及制备方法和应用
MX2024005933A (es) * 2021-11-17 2024-08-06 Chdi Foundation Inc Moduladores de htt pata tratar la enfermedad de huntington.
WO2023113023A1 (ja) 2021-12-17 2023-06-22 佐藤製薬株式会社 Ｈ－ｐｇｄｓを阻害するアザインドール誘導体

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03112985A (ja) * 1989-09-28 1991-05-14 Morishita Pharmaceut Co Ltd Ｎ―（１ｈ―テトラゾール―５―イル）―２―フェニル―５―ピリミジンカルボキシアミド類及びその合成用中間体
GB9405347D0 (en) * 1994-03-18 1994-05-04 Agrevo Uk Ltd Fungicides
JP2000226372A (ja) * 1999-02-01 2000-08-15 Nippon Soda Co Ltd アミド化合物、その製造方法及び農園芸用殺虫剤
US7115750B1 (en) * 1999-09-20 2006-10-03 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonist
JP2002003370A (ja) * 1999-09-20 2002-01-09 Takeda Chem Ind Ltd メラニン凝集ホルモン拮抗剤
MY138097A (en) * 2000-03-22 2009-04-30 Du Pont Insecticidal anthranilamides
JP2003112985A (ja) 2001-10-01 2003-04-18 Nre Happiness Kk 食品残渣肥、飼料原料化システムおよびそれに使用する破砕貯留処理ユニット並びに乾燥冷却処理ユニット
AU2003248122A1 (en) * 2002-07-25 2004-02-16 Kotobuki Pharmaceutical Co., Ltd. Sodium channel inhibitor
AU2003252715B2 (en) * 2002-07-30 2009-06-04 Banyu Pharmaceutical Co., Ltd. Antagonist of melanin-concentrating hormone receptor comprising benzimidazole derivative as active ingredient
ATE450533T1 (de) * 2003-02-14 2009-12-15 Glaxo Group Ltd Carboxamidderivate
DK1471057T3 (da) * 2003-04-25 2006-05-15 Actimis Pharmaceuticals Inc Pyrimidinyleddikesyrederivater, der er egnede til behandlingen af sygdomme medieret af CRTH2
GB2406856B (en) * 2003-10-07 2005-10-19 Renovis Inc Amide compounds as ion channel ligands and uses thereof
EP1737414A2 (en) * 2004-01-23 2007-01-03 Amgen Inc. Vanilloid receptor ligands and their use in treatments of inflammatory and neuropatic pain
DOP2006000210A (es) 2005-10-04 2007-06-15 Aventis Pharma Inc Compuestos de pirimidina amida como inhibidores de pgds

Also Published As

Publication number Publication date
PE20070589A1 (es) 2007-06-22
RU2420519C2 (ru) 2011-06-10
CA2624749C (en) 2011-08-16
CN101538246A (zh) 2009-09-23
ES2514471T3 (es) 2014-10-28
TNSN08104A1 (en) 2009-07-14
AR056871A1 (es) 2007-10-31
SG166121A1 (en) 2010-11-29
CN101538246B (zh) 2014-07-16
MA29925B1 (fr) 2008-11-03
NO20082000L (no) 2008-06-09
JP5452925B2 (ja) 2014-03-26
UY29840A1 (es) 2007-05-31
TWI415839B (zh) 2013-11-21
IL190411A0 (en) 2008-11-03
ZA200802222B (en) 2009-09-30
AU2006299428A1 (en) 2007-04-12
CR9832A (es) 2008-06-18
CN101282943A (zh) 2008-10-08
IL190411A (en) 2013-09-30
EP1937652A1 (en) 2008-07-02
NZ567208A (en) 2011-03-31
BRPI0616815A2 (pt) 2011-07-05
EP1937652B1 (en) 2014-07-30
ECSP088335A (es) 2008-05-30
TW200812977A (en) 2008-03-16
CA2624749A1 (en) 2007-04-12
KR20080050611A (ko) 2008-06-09
RU2008117170A (ru) 2009-11-10
US20080227782A1 (en) 2008-09-18
PE20110118A1 (es) 2011-03-08
MY151172A (en) 2014-04-30
US8202863B2 (en) 2012-06-19
AU2006299428B2 (en) 2012-04-26
WO2007041634A1 (en) 2007-04-12
KR101457966B1 (ko) 2014-11-04
UA93213C2 (en) 2011-01-25
JP2009510170A (ja) 2009-03-12

Similar Documents

Publication Publication Date Title
DOP2006000210A (es) Compuestos de pirimidina amida como inhibidores de pgds
MY154895A (en) Pyrimidine hydrazide compounds as pgds inhibitors
SV2009002861A (es) Compuestos de pirimidina amida como inhibidores de pgds
ECSP14013173A (es) 3,5-diamino-6-cloro-n-(n-(4-(4-(2-(hexil(2,3,4,5,6-pentahidroxihexil)amino)etoxi)fenil)butil) carbamimidoil)pirazina-2-carboxamida
BR0107934A (pt) Carboxamidas de pirimidina úteis como inibidores de isozimas pde4
SV2008003045A (es) Aminotetrahidropiranos como inhibidores de dipertidil, peptidasa-iv para el tratamiento o prevencion de diabetes
AR078552A1 (es) Derivados de feniloxadiazol como agentes inhibidores de las pgds
NO20084005L (no) Aminderivater
NI201100081A (es) Aminotetrahidropiranos como inhibidores de dipeptidil peptidasa - iv para el tratamiento o prevención de diabetes.
GT200900289A (es) Compuestos organicos.-
NO20075113L (no) Proteinkinaseinhibitorer
PE20070362A1 (es) COMPUESTOS DERIVADOS DE INDAZOL-4-IL-2,4-PIRIMIDINDIAMINA COMO INHIBIDORES DE TIROSINA QUINASA (QUINASA Syk)
CL2011002463A1 (es) Compuestos heterociclicos, agonistas del receptor de glucocorticoide; composicion farmaceutica que comprende a dicho compuesto; composicion farmaceutica; kit farmaceutico; uso del compuesto para tratar el asma, enfermedad pulmonar obstructiva cronica o rinitis alergica.
PE20070828A1 (es) Composicion farmaceutica que contiene una sal de glicopirronio
CL2011002461A1 (es) Compuestos derivados de tipo amida de compuestos [3,2-c] pirazol con actividad glucocorticoide utiles en condiciones inflamatorias y alergicas como asma, epoc o rinitis alergica.
PE20070794A1 (es) Compuestos de cinolina como inhibidores de fosfodiesterasa tipo iv (pdeiv)
EA201070927A1 (ru) Двойные фармакофоры-pde4-мускариновые антагонисты
EA201070917A1 (ru) Двойные фармакофоры - pde4-мускариновые антагонисты
UY30988A1 (es) Compuestos de pirimidina hidrazida como inhibidores de pgds
AR062566A1 (es) Compuestos de pirazolo (3,4-b]piridina, un procedimiento para su preparacion y composicion farmaceutica
CL2012000885A1 (es) Compuestos derivados de feniloxadiazol, inhibidores de las prostaglandinas sintasa (pgds); procedimiento de preparacion de dichos compuestos; compuestos intermediarios; composicion farmaceutica que comprende dichos compuestos, util para tratar un trastorno inflamatorio o alergico.
BRPI0509137A (pt) compostos para o tratamento de doenças
TH105528A (th) สารประกอบไพริมิดีน เอไมด์ ที่เป็นสารยับยั้งพรอสตาแกลนดิน
CL2011001061A1 (es) Compuestos derivados de pirazolona, inhibidores de fosfodiesterasa tipo 4 (pdea); composicion farmaceutica; y uso para el tratamiento o la profilaxis de una enfermedad aguda o cronica de las vias respiratorias, tal como bronquitis, asma, enfisema y para el tratamiento o profilaxis de rinitis alergica.
AR072645A1 (es) Composicion farmacologica con contenido de pirazolopirimidinona o sus sales aceptables para uso farmaceutico para la prevencion y tratamiento de enfermedades respiratorias